Literature search services are currently unavailable. During our hosting provider's UPS upgrade we experienced a hardware failure and are currently working to resolve the issue.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in approximately 60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus represents an important therapeutic target in melanoma. In an effort to produce a pre-clinical model of mutant BRAF function in melanoma, we have generated a mouse expressing BRAF V600E targeted to melanocytes. We show that in these transgenic mice, widespread benign melanocytic hyperplasia with histological features of nevi occurs, with biochemical evidence of senescence. Melanocytic hyperplasia progresses to overt melanoma with an incidence dependent on BRAF expression levels. Melanomas show CDKN2A loss, and genetic disruption of the CDKN2A locus greatly enhances melanoma formation, consistent with collaboration between BRAF activation and CDKN2A loss suggested from studies of human melanoma. The development of melanoma also involves activation of the Mapk and Akt signaling pathways and loss of senescence, findings that faithfully recapitulate those seen in human melanomas. This murine model of mutant BRAF-induced melanoma formation thus provides an important tool for identifying further genetic alterations that cooperates with BRAF and that may be useful in enhancing susceptibility to BRAF-targeted therapeutics in melanoma.

Pubmed ID: 19398955


  • Goel VK
  • Ibrahim N
  • Jiang G
  • Singhal M
  • Fee S
  • Flotte T
  • Westmoreland S
  • Haluska FS
  • Hinds PW
  • Haluska FG



Publication Data

June 11, 2009

Associated Grants

  • Agency: NCI NIH HHS, Id: CA095798
  • Agency: NCI NIH HHS, Id: R01 CA095798
  • Agency: NCI NIH HHS, Id: R01 CA095798-03
  • Agency: NCI NIH HHS, Id: R01 CA095798-04
  • Agency: NCI NIH HHS, Id: R01 CA095798-05

Mesh Terms

  • Amino Acid Substitution
  • Animals
  • Animals, Newborn
  • Blotting, Southern
  • Cell Aging
  • Cell Line, Tumor
  • Cells, Cultured
  • Cyclin-Dependent Kinase Inhibitor p16
  • Gene Expression Profiling
  • Humans
  • Melanocytes
  • Melanoma
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Mutation
  • Nevus
  • Proto-Oncogene Proteins B-raf
  • Reverse Transcriptase Polymerase Chain Reaction
  • Schwann Cells
  • Skin Neoplasms
  • Tumor Suppressor Protein p53